User login
Browse archives
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
Who's online
Syndicate
Finally, An Unbiased Drug Source Has Arrived...
Herb Denenberg, a former Pennsylvania insurance commissioner and professor at the Wharton School, is a longtime Philadelphia journalist and consumer advocate. He is also a member of the National?Academy of Arts and Sciences. His column appears daily in The Bulletin. You can reach him at advocate@thebulletin.us.
"The editorial process used for Medical Letter publications relies on a consensus of experts to develop prescribing recommendations. An expert consultant or one of our editors prepares the preliminary report on a drug in terms of the effectiveness, adverse effects and possible alternatives. Both published and available unpublished studies are carefully examined, paying special attention to the results of controlled clinical trials. The preliminary draft is edited and sent to every member of the Advisory Board of the Medical Letter, to 10-20 other consultants who have clinical and experimental experience with the drug or type of drug under review, to the FDA and sometimes the CDC, to private representatives of the pharmaceutical companies making the drug under review, and often to companies that make competing drugs as well. Many critical comments and corrections are received from the reviewers and incorporated into the article during the revision process. The final publication is considered a crucial resource for members of the healthcare community to consult when they are overwhelmed by advertisements and personal visits from sales representatives of the pharmaceutical industry."
Source: The Medical Letter, Conclusions 2006 (Copyright 2007).
This is cache, read story here